TrialClinical drug investigation2012

Monthly administration of a continuous erythropoietin receptor activator provides efficient haemoglobin control in non-dialysis patients during routine clinical practice: results from the non-interventional, single-cohort, multicentre, SUPRA study.

Stefan Heidenreich et al.PubMed ↗Publisher ↗

No numbers read from the abstract.